Tilray Medical Announces Commercial Launch of Medical Cannabis in Panama, Expanding Patient Access Across Latin America

About this update from Tilray Brands, Inc.

Launch of Tilray Medical's first medical cannabis product in Panama strengthens the company's international footprint and supports broader access to regulated cannabinoid-based medicines PANAMA CITY, July 09, 2026 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY) and a leading global medical cannabis company, today announced the commercial launch of its first medical cannabis product in Panama, marking a significant milestone in the company's ongoing global expansion and commitment to improving patient access to pharmaceutical-grade cannabinoid medicines worldwide. The launch follows the successful shipment of Tilray Oral Solution CBD100 from Tilray Medical's EU-GMP-certified production facilities in Portugal through its joint venture with Solana Life Group S. de R.L. The product is intended to be distributed through Farmacias Arrocha , one of Panama's leading pharmacy networks, where patients will be able to access Tilray Oral Solution CBD 100 under medical prescription. This is expected to provide patients and healthcare professionals with access to regulated, pharmaceutical-quality medical cannabis through established healthcare channels. The milestone reinforces Tilray Medical's position as one of the most geographically diversified medical cannabis companies globally. Today, Tilray Medical serves patients across more than 20 countries spanning Europe, Australia, Canada, Latin America, and other emerging international markets, helping advance access to safe, high-quality cannabinoid-based medicines through regulated healthcare systems. Rajnish Ohri, President, International, Tilray Brands, stated, "At Tilray Medical, we believe every patient deserves access to safe, consistent, pharmaceutical-grade medical cannabis products. Our commercial launch in Panama reflects our broader vision to expand access to cannabinoid-based medicines through trusted healthcare systems around the world. As medical cannabis frameworks continue to advance, we are committed to working alongside healthcare providers, regulators, pharmacists, and patients to help shape the future of responsible access, advance medical education, and deliver high-quality treatment options that improve lives." The launch supports Panama's emerging medical cannabis framework established under Law 242 of 2021 and follows important regulatory advancements by the Ministry of Health, including Resolution No. 0406 of May 12, 2026, which established key requirements for patient access. The Ministry also recently introduced the Medical Cannabis Users and Authorized Caregivers Identification System (SIUCMAA), creating a structured pathway for physician authorization and patient registration.

View stock analysis, news, and events for Tilray Brands, Inc.